Skip to main content
Sister Publication Links
  • ESG: THE NEW IMPERATIVE
Subscribe
  • My Account
  • Login
  • Subscribe
  • News
    • Current News
    • COVID-19
    • Providers
    • Insurance
    • Government
    • Finance
    • Technology
    • Safety & Quality
    • Transformation
    • People
    • Regional News
    • Digital Edition (Web Version)
    • Patients
    • Operations
    • Care Delivery
    • Payment
    • Midwest
    • Northeast
    • South
    • West
  • Digital Health
  • Insights
    • ACA 10 Years After
    • Best Practices
    • Special Reports
    • Innovations
  • Data/Lists
    • Rankings/Lists
    • Interactive Databases
    • Data Points
  • Opinion
    • Bold Moves
    • Breaking Bias
    • Commentaries
    • Letters
    • Vital Signs Blog
    • From the Editor
  • Events & Awards
    • Awards
    • Conferences
    • Galas
    • Virtual Briefings
    • Custom Media Event: ESG Summit
    • Webinars
    • Nominate/Eligibility
    • 100 Most Influential People
    • 50 Most Influential Clinical Executives
    • Best Places to Work in Healthcare
    • Excellence in Governance
    • Health Care Hall of Fame
    • Healthcare Marketing Impact Awards
    • Top 25 Emerging Leaders
    • Top 25 Innovators
    • Diversity in Healthcare
      • - Luminaries
      • - Top 25 Diversity Leaders
      • - Leaders to Watch
    • Women in Healthcare
      • - Luminaries
      • - Top 25 Women Leaders
      • - Women to Watch
    • Leadership Symposium
    • Social Determinants of Health Symposium
    • Transformation Summit
    • Women Leaders in Healthcare Conference
    • Best Places to Work Awards Gala
    • Health Care Hall of Fame Gala
    • Top 25 Diversity Leaders Gala
    • Top 25 Women Leaders Gala
    • - Hospital of the Future
    • - Value Based Care
    • - Supply Chain Revenue Cycle
    • - Hospital at Home
    • - Workplace of the Future
    • - Virtual Health
    • - Future of Healthcare Staffing
  • Multimedia
    • Podcast - Beyond the Byline
    • Sponsored Podcast - Healthcare Insider
    • Video Series - The Check Up
    • Sponsored Video Series - One on One
  • MORE +
    • Advertise
    • Media Kit
    • Newsletters
    • Jobs
    • People on the Move
    • Reprints & Licensing
MENU
Breadcrumb
  1. Home
  2. Government
April 03, 2019 04:45 PM

Medicare drug price arbitration gains steam in the House

Susannah Luthi
  • Tweet
  • Share
  • Share
  • Email
  • More
    Reprints Print
    Getty Images/Tetra images RF

    House Ways and Means Committee Chair Richard Neal (D-Mass.) will broach the idea of using arbitration to give HHS leverage with drug manufacturers over prices in a hearing next Tuesday.

    The committee plans to convene a hearing to discuss a bipartisan set of bills aimed at drug price transparency, the chairman said. But he said that he and the panel's Ranking Member Kevin Brady (R-Texas) have discussed arbitration "in a general way" in their regular talks. He described those talks as "fluid," but confirmed that a policy like arbitration is possible.

    Brady told Modern Healthcare he has just begun to look at the policy, and declined to signal what his position might be.

    Neal's comment came as Democrats are getting antsy for discussion of more sweeping policy that gets at their party's promises on drug price negotiation, and as lawmakers from both parties feel out how far they're willing to go on a package that has the backing of the White House yet also needs to navigate the demands of House Democratic progressives and the GOP-led Senate.

    Whatever policy the House settles on needs to originate through the committee process, said Drew Hammill, deputy chief of staff for House Speaker Nancy Pelosi (D-Calif.). The Ways and Means and Energy and Commerce committees share jurisdiction over the issue.

    Tuesday's hearing will be the first legislative discussion for Ways and Means, while the Energy and Commerce Committee on Wednesday reached bipartisan agreement on measures to boost generic competition.

    "I don't know what the hesitation is personally," Rep. Peter DeFazio (D-Ore.) said, regarding the lag in introducing a more sweeping policy. "The people dislike drug companies more than they do Congress, and if we took on the drug companies, they may even like us a little better."

    Rep. Peter Welch (D-Vt.), who sits on the Energy and Commerce Committee, said lawmakers need to "land the ship at some point." As work continues, he expects to get more specifics on whether Democrats land on a formulary or arbitration as the Medicare leverage with drug companies.

    Still, he said he worries the final deal could ultimately fail to give that leverage to HHS.

    "The bottom line is, I think we probably will get to the point where people like me want to do a good deal more than our counterparts," he said. "But we'll see, and I think it's going to be whatever we can do together. That's good, it gives a foundation, but at the end of the day we've got to have real authority for the secretary to do on behalf of American consumers and taxpayers what all other countries do, as a counterweight to the monopoly pricing."

    Much of the task for generating enthusiasm among Republicans could fall to the White House. The administration raised conservatives' eyebrows last fall when it announced a proposed demonstration to set an international reference price for Medicare Part B drugs.

    "I want to work with Democrats and the administration," said Rep. Gus Bilirakis (R-Fla.), who sits on the Energy and Commerce Committee.

    He said he is open to an arbitration policy and he hopes Congress can coalesce around a substantive idea because "of course my constituents want that more than anything."

    While talk ramps up about arbitration, it's still unclear whether that will be the policy lawmakers will settle on, and also which committee will propose the "bold" policies Democrats hope for.

    In Ways and Means, the leader of the health subcommittee is Rep. Lloyd Doggett (D-Texas). He has a bill that would let HHS license generics if a brand manufacturer doesn't agree to a price deemed reasonable. It has the support of progressive Democrats, but is considered a nonstarter because it lets the HHS secretary override patent exclusivity rights.

    In Energy and Commerce, Rep. Anna Eshoo (D-Calif.) chairs the health panel. Last week she told Modern Healthcare she is focused for now on the measures currently moving through the committee.

    Meanwhile, House progressives are rallying around Doggett's bill, as they told Pelosi's health deputy Wendell Primus in a Tuesday meeting.

    Congressional Progressive Caucus Chair Pramila Jayapal (D-Wash.) said her group's discussion with Primus largely didn't yield any breakthroughs, but that lawmakers articulated their position.

    "We have been very clear that we need a bold solution to the drug pricing issue," Jayapal said. "It's off the charts for our constituents across the country, so we wanted to make it very clear that it needs to be something bold that has teeth in it. And I believe that is what Rep. Doggett's bill has in it."

    When asked for a sense of where leadership stands in terms of its ambitions, she said it's "hard to know."

    For all the Democratic momentum, the GOP-led Senate also needs to be convinced for anything to pass. Rep. Tom Reed (R-N.Y.), who sits on the Ways and Means Committee and co-chairs the moderate bipartisan Problem Solvers Caucus, expressed skepticism that anything hinting at Medicare negotiation could secure enough support.

    He said ideas such as arbitration require "a longer conversation" and right now he thinks it's more realistic to focus on transparency measures given the need for 60 votes in the Senate for any bill.

    "Before we get to that bigger debate and more complicated debate about how do you reincentivize or restructure the Medicaid and Medicare programs to force prices to go down, you've got to get the data so we go in with the best information possible," he said.

    Still, the White House remains the wild-card factor for Republicans and drug pricing reform is the administration's top agenda item.

    "We share the common interest of lowering drug prices and are having ongoing conversations to see where we can work together," a White House official said of the administration's meetings with Pelosi's office, although he did not disclose specifics.

    Letter
    to the
    Editor

    Send us a letter

    Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.

    Recommended for You
    medicare and money
    Inspector General pushes CMS to recover $226M in Medicare overpayments
    Ezike 800.jpg
    Former Illinois health chief Ezike under scrutiny by state's top ethics investigator
    Sponsored Content
    Modern Healthcare Alert: Sign up for this breaking news email to be kept in the loop as urgent healthcare business news unfolds.
    Get Newsletters

    Sign up for enewsletters and alerts to receive breaking news and in-depth coverage of healthcare events and trends, as they happen, right to your inbox.

    Subscribe Today
    MH Magazine Cover

    MH magazine offers content that sheds light on healthcare leaders’ complex choices and touch points—from strategy, governance, leadership development and finance to operations, clinical care, and marketing.

    Subscribe
    Connect with Us
    • LinkedIn
    • Twitter
    • Facebook
    • RSS

    Our Mission

    Modern Healthcare empowers industry leaders to succeed by providing unbiased reporting of the news, insights, analysis and data.

    Contact Us

    (877) 812-1581

    Email us

     

    Resources
    • Contact Us
    • Advertise with Us
    • Ad Choices Ad Choices
    • Sitemap
    Editorial Dept
    • Submission Guidelines
    • Code of Ethics
    • Awards
    • About Us
    Legal
    • Terms and Conditions
    • Privacy Policy
    • Privacy Request
    Modern Healthcare
    Copyright © 1996-2022. Crain Communications, Inc. All Rights Reserved.
    • News
      • Current News
      • COVID-19
      • Providers
      • Insurance
      • Government
      • Finance
      • Technology
      • Safety & Quality
      • Transformation
        • Patients
        • Operations
        • Care Delivery
        • Payment
      • People
      • Regional News
        • Midwest
        • Northeast
        • South
        • West
      • Digital Edition (Web Version)
    • Digital Health
    • Insights
      • ACA 10 Years After
      • Best Practices
      • Special Reports
      • Innovations
    • Data/Lists
      • Rankings/Lists
      • Interactive Databases
      • Data Points
    • Opinion
      • Bold Moves
      • Breaking Bias
      • Commentaries
      • Letters
      • Vital Signs Blog
      • From the Editor
    • Events & Awards
      • Awards
        • Nominate/Eligibility
        • 100 Most Influential People
        • 50 Most Influential Clinical Executives
        • Best Places to Work in Healthcare
        • Excellence in Governance
        • Health Care Hall of Fame
        • Healthcare Marketing Impact Awards
        • Top 25 Emerging Leaders
        • Top 25 Innovators
        • Diversity in Healthcare
          • - Luminaries
          • - Top 25 Diversity Leaders
          • - Leaders to Watch
        • Women in Healthcare
          • - Luminaries
          • - Top 25 Women Leaders
          • - Women to Watch
      • Conferences
        • Leadership Symposium
        • Social Determinants of Health Symposium
        • Transformation Summit
        • Women Leaders in Healthcare Conference
      • Galas
        • Best Places to Work Awards Gala
        • Health Care Hall of Fame Gala
        • Top 25 Diversity Leaders Gala
        • Top 25 Women Leaders Gala
      • Virtual Briefings
        • - Hospital of the Future
        • - Value Based Care
        • - Supply Chain Revenue Cycle
        • - Hospital at Home
        • - Workplace of the Future
        • - Virtual Health
        • - Future of Healthcare Staffing
      • Custom Media Event: ESG Summit
      • Webinars
    • Multimedia
      • Podcast - Beyond the Byline
      • Sponsored Podcast - Healthcare Insider
      • Video Series - The Check Up
      • Sponsored Video Series - One on One
    • MORE +
      • Advertise
      • Media Kit
      • Newsletters
      • Jobs
      • People on the Move
      • Reprints & Licensing